Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»Business

    Decongestant found in many cold, allergy medicines doesn’t actually work, FDA advisors say

    AdminBy AdminSeptember 12, 2023 Business
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    In this article

    • PG
    A combination package of Procter & Gamble Co. DayQuil Severe and NyQuil Severe brand cold and flu medicine is arranged for a photograph in Tiskilwa, Illinois.
    Daniel Acker | Bloomberg | Getty Images

    The main ingredient used in many popular over-the-counter cold and allergy medications doesn’t actually work to get rid of nasal congestion, an advisory panel to the Food and Drug Administration declared Tuesday. 

    In a unanimous vote, 16 advisors said oral versions of phenylephrine – a nasal decongestant found in versions of drugs like Nyquil,  Benadryl, Sudafed and Mucinex – aren’t effective at relieving a stuffy nose. 

    The FDA typically follows the advice of its advisory committees but it is not required to do so. The agency could potentially move to begin a process that removes phenylephrine from the market, which would force manufacturers to pull widely used cough and cold medications from store shelves and reformulate those products. 

    That could affect Procter & Gamble, the manufacturer of all versions of Nyquil, and the Johnson & Johnson spinoff Kenvue, which manufactures Tylenol and Benadryl products. Drugs with phenylephrine generated $1.8 billion in sales last year, according to data presented Monday by FDA staff. 

    A spokesperson for the Consumer Healthcare Products Association, a trade organization representing manufacturers and distributors of OTC drugs, didn’t immediately respond to a request for comment on the advisory panel’s vote.

    CNBC Health & Science

    Read CNBC’s latest health coverage:

    • Pfizer beats on earnings, but revenue misses as Covid product sales plummet
    • Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
    • NIH to test Pfizer’s Paxlovid, other treatments as potential long Covid therapies

    Pulling cough and cold pills from the market could also force consumers to switch to entirely new medications or liquid and spray versions of phenylephrine, which were not included in the review by the FDA advisors. 

    The two-day advisory panel meeting was prompted by researchers at the University of Florida, who petitioned the FDA to remove phenylephrine products based on recent studies showing they failed to outperform placebo pills in patients with cold and allergy congestion. 

    The same researchers also challenged the drug’s effectiveness in 2007, but the FDA allowed the products to remain on the market pending additional research.

    Yet FDA staff, in briefing documents posted ahead of the meeting this week, concluded that oral formulations of phenylephrine don’t work at standard or even higher doses. A very small amount of the drug actually reaches the nose to relieve congestion, the agency’s staff said.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Noa Argamani Shares the Philosophy She Lives by

    October 31, 2026

    What Does the Weil Gotshal Implosion Mean for the Law-Firm Industry?

    October 30, 2026

    AI-Controlled Gun Turrets Are Becoming a Reality of War

    October 30, 2026

    A $1,000 Device Enables Hands-Free Driving. But Fatal Crashes Have Prompted Scrutiny.

    October 29, 2026

    NATO’s Drone-Predicting AI Gives Troops a Map of Tomorrow’s Strikes

    October 29, 2026

    Weil Gotshal Leaders Discussing Plan to Wind Down Law Firm

    October 28, 2026
    Popular Posts

    ESI supplying solar array components to missile defense programs

    ICE activity is surging ahead of midterms. So is voter turnout. : NPR

    What Does the Weil Gotshal Implosion Mean for the Law-Firm Industry?

    Judge fast tracks bids to dismiss DOJ lawsuit

    Stephen King Leads October’s Thrill List

    10 Best Date Night Colognes For Men In 2026

    Categories
    • Books (2,422)
    • Business (3,414)
    • Events (33)
    • Film (1,024)
    • LifeStyle (2,889)
    • Music (2,758)
    • Politics (2,323)
    • Science (1,917)
    • Technology (1,788)
    • Television (3,591)
    • Uncategorized (3)
    • US News (3,268)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • ‘DWTS’ Fans Question Season 35, ‘Domestic Violence’ References‘DWTS’ Fans Question Season 35, ‘Domestic Violence’ References
    • Auto industry braces for contentious contract talks as UAW formally kicks off bargaining
    • Easy-to-use calculation tool estimates out-of-field neutron dose during proton therapy – Physics WorldEasy-to-use calculation tool estimates out-of-field neutron dose during proton therapy – Physics World
    • 7 Books About Objects That Changed the World
    • Nike (NKE) earnings Q1 2025Nike (NKE) earnings Q1 2025
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • Uncategorized
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.